RH-EPO NASAL FORMULATIONS WITH LOW SIALIC ACID CONCENTRATION FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

• Main Authors: DAVID CURBELO RODRIGUEZ D, ZENIA PARDO RUIZ Z, ADRIANA MUNOZ CERNADA A, NELVYS SUBIROS MARTINEZ N, JULIO CESAR GARCIA RODRIGUEZ JC, JORGE DANIEL GARCIA SELMAN JD, JANETTE CRUZ RODRIGUEZ J, ILIANA SOSA TESTE I, YANIER NUNEZ FIGUEREDO Y
• Format: Patent
• Language: Chinese; English
• Published: 16.12.2016
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention is related to the biopharmaceutical industry and in particular to the development of a medication for the treatment of cerebrovascular, neurodegenerative and psychiatric diseases. Its active principle is recombinant human erythropoietin (rhEPO) with low content of sialic acid. During the production of rhEPO, this glycoprotein is obtained with different contents of sialic acid; if less than 40% of the molecule is protected with (basic) sialic acid, it is not biologically active in the systemic way, as it is then inactivated by hepatic enzymes. Surprisingly, we have found that intranasal administration of basic rhEPO has enhanced therapeutic activity in comparison with acid rhEPO. The nasal formulations of basic rhEPO herein presented incorporate bioadhesive polymers which increase the residence time in the nasal cavity, thereby enhancing their therapeutic effect. They also include other auxiliary substances such as preservatives, tensioactive agents, pH regulators, isotonic agents and pro